<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: Rheumatoid</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Fri, 24 Sep 2021 05:00:00 GMT</pubDate>
  <item>
    <title>SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis</title>
    <pubDate>Fri, 24 Sep 2021 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/217805352.html</link>
    <description></description>
    <source>DI</source>
  </item>


  <item>
    <title>SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021</title>
    <pubDate>Fri, 20 Aug 2021 06:30:00 GMT</pubDate>
    <link>https://www.pressen.se/176183867.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.</title>
    <pubDate>Fri, 14 May 2021 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/56723686.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version</title>
    <pubDate>Tue, 04 May 2021 06:00:00 GMT</pubDate>
    <link>https://www.pressen.se/45452759.html</link>
    <description></description>
    <source>DI</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.089623928070068 s -->